Verona Pharma plc — Director's Dealing 2025

May 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2025-05-20

Reporting Person: Sinha Vikas (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-20	Ordinary Shares	M	160000	$0.5038	Acquired	234440	Direct
2025-05-20	Ordinary Shares	S	160000	$9.3933	Disposed	74440	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-20	Share Options (Right to Buy)	$0.5038	M	160000	Disposed	2032-04-27	Ordinary Shares (160000)	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2024.

F3: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $9.375 to $9.4263, inclusive (or $75.00 to $75.41 per ADS, inclusive). The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.

F4: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.

F5: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F6: The option is fully vested.